Adocia and Tonghua Dongbao Report Phase 3 Success for Ultra-Rapid Insulin

Adocia and Tonghua Dongbao have announced positive results from a Phase 3 trial in China for BioChaperone® Lispro (THDB0206), an ultra-rapid insulin. Conducted on adults with Type 2 diabetes, the study confirmed the new insulin's non-inferiority to Humalog® in reducing HbA1c levels over 26 weeks, the primary endpoint. Additionally, it showed a significant reduction in postprandial blood glucose rise, a key secondary endpoint.

The trial, involving 1,040 participants, demonstrated a statistically improved mean daily blood glucose level, supporting the product's benefits in long-term glucose control. The safety profile was favorable, with mild to moderate adverse events comparable to those of Humalog®.

This breakthrough positions Adocia and Tonghua Dongbao as innovators in diabetes treatment, advancing the company’s strategic goals under a long-standing partnership.